REGENXBIO Inc. (RGNX)
| Market Cap | 1.70B |
| Revenue (ttm) | 154.57M |
| Net Income (ttm) | -111.25M |
| Shares Out | 37.28M |
| EPS (ttm) | -2.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $40.27 |
| Previous Close | $39.93 |
| Change ($) | 0.34 |
| Change (%) | 0.85% |
| Day's Open | 39.93 |
| Day's Range | 39.01 - 40.82 |
| Day's Volume | 99,208 |
| 52-Week Range | 20.03 - 50.26 |
Regenxbio (RGNX) delivered earnings and revenue surprises of -211.71% and -83.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Regenxbio (NASDAQ:RGNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.22% over the past year to ($1.24), which miss...
ROCKVILLE, Md., March 1, 2021 /PRNewswire/ -- Pivotal program for subretinal delivery of RGX-314 for the treatment of wet AMD is active and enrolling patients; expected to support BLA filing i...
ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following March investor conferences, which will each be held in a virtua...
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regenxbio Inc (NASDAQ: RGNX) has reported additional interim data from Cohorts 4 and 5 of its Phase 1/2a trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (wet...
ROCKVILLE, Md., Feb. 16, 2021 /PRNewswire/ -- RGX-314 using subretinal delivery continues to be generally well-tolerated at all dose levels Positive interim update from Cohorts 4 and 5 at 1.5 ...
ROCKVILLE, Md., Feb. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that additional positive interim data from a total of eight patients in Cohorts 1 and 2 of the ongoin...
ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 c...
ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, t...
ROCKVILLE, Md., Jan. 12, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced underwritten public offering of 4,260,000 shares of its comm...
ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 a...
ROCKVILLE, Md., Jan. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 4,260,000 shares of its common stock at the price o...
Regenxbio launched a key study of its eye disease-targeting gene therapy, prompting RGNX stock to pop on Wednesday. It's also planning to test a gene therapy in muscular dystrophy.
ROCKVILLE, Md., Jan. 6, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therap...
REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy
These three small-cap stocks all turned a profit last quarter and present ample growth potential at bargain prices.
ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for...
ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene ther...
Back in 2019, the Zolgensma approval validated Regenxbio's NAV technology platform for gene delivery. Despite a slow start, Zolgensma recently hit $1B in cumulative sales. Regenxbio's organic ...
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
ROCKVILLE, Md., Dec. 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene ther...
ROCKVILLE, Md., Dec. 8, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene thera...
ROCKVILLE, Md., Dec. 1, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene thera...
ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene ther...
REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q3 2020 Results - Earnings Call Transcript
Regenxbio (RGNX) delivered earnings and revenue surprises of 125.84% and 284.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Regenxbio (NASDAQ:RGNX) were flat after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 124.47% over the past year to $0.23, whic...
ROCKVILLE, Md., Oct. 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene ther...
It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.
Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interes...
ROCKVILLE, Md., Sept. 30, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene the...
ROCKVILLE, Md., Sept. 25, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene the...
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduci...
ROCKVILLE, Md., Sept. 9, 2020 /PRNewswire/ -- REGENXBIO Inc.
ROCKVILLE, Md., Aug. 25, 2020 /PRNewswire/ -- REGENXBIO Inc.
REGENXBIO's (RGNX) CEO Ken Mills on Q2 2020 Results - Earnings Call Transcript
Regenxbio (RGNX) delivered earnings and revenue surprises of -2.25% and -14.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., Aug. 6, 2020 /PRNewswire/ -- REGENXBIO Inc.
ROCKVILLE, Md., Aug. 4, 2020 /PRNewswire/ -- Company on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020 RGX-314 was generally well-tolerated in 42 patients at ...
ROCKVILLE, Md., July 30, 2020 /PRNewswire/ -- REGENXBIO Inc.
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROCKVILLE, Md., July 8, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene thera...
ROCKVILLE, Md., June 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene thera...
With the COVID-19 pandemic being the biggest health care story in years, it is no surprise that investors and traders have been closely watching and have been doing analysis on the top compani...
Companies that have been able to deliver compelling results have been acquired by big pharma companies (for instance, Spark Therapeutics was acquired by Roche), while others have underperforme...
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q1 2020 Results - Earnings Call Transcript
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About RGNX
REGENXBIO, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is als... [Read more...]
| Industry Biotechnology | IPO Date Sep 17, 2015 |
| CEO Kenneth Mills | Employees 257 |
| Stock Exchange NASDAQ | Ticker Symbol RGNX |
Financial Performance
In 2020, REGENXBIO Inc.'s revenue was $154.57 million, an increase of 338.70% compared to the previous year's $35.23 million. Losses were -$111.25 million, 17.4% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for REGENXBIO Inc. stock is "Buy." The 12-month stock price forecast is 63.78, which is an increase of 58.38% from the latest price.